Menu

The Fatty Acid–Ketone Switch

In failing hearts, cardiomyocytes change their fuel preference.

Jun 1, 2016
Amanda B. Keener

Healthy cardiomyocytes (left panel) mainly use fatty acids as their energy source. To produce ATP, fatty acids are first converted into acylcarnitines, which are converted back to fatty-acyl-CoA and enter the β-oxidation cycle inside mitochondria. The resulting acetyl-CoAs then enter the citric acid cycle. In a mouse model of heart failure and in failing human hearts (right panel), cardiomyocytes depend more on ketones for energy. The ketone βOHB enters the mitochondrion where the enzyme BDH1 converts it into acetoacetate, whose products serve as substrates for the citric acid cycle. Both mice and humans with heart failure experience increased serum levels of βOHB, but in human cells βOHB and acylcarnitine levels go down. In mice, heart failure reduces the abundance of proteins involved in fatty acid oxidation. Both alterations suggest ketones are preferred over fatty acids in failing hearts.

THE SCIENTIST STAFF

Read the full story.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.